

Unaudited Interim Condensed Consolidated Financial Statements of

MOUNTAIN VALLEY MD HOLDINGS INC.

For the six months period ended September 30, 2022 and 2021

Interim Condensed Consolidated Statements of Financial Position (Unaudited, in thousands of Canadian Dollars)

	Note	September 30, 2022		March 31, 2022	
Current Assets Cash and cash equivalents		\$	12,623	\$	14,221
HST recoverable		Ŧ	93	Ŧ	87
Purchase consideration receivable	3		74		-
Prepaids, deposits and other	4		480		605
Note receivable			115		112
Right of use asset			27		46
		. <u> </u>	13,412		15,071
Long-term Assets					
Intangible assets	5		4,357		4,518
Equity investments	6		3,038		5,028
Investment in associate			-		426
Capital assets			200		227
			7,595		10,199
		\$	21,007	\$	25,270
TOTAL LIABILITIES AND SHAREHOLDER'S EQUITY Current Liabilities					
Accounts payable and accrued liabilities		\$	560	\$	238
Deferred revenue			140		140
Lease liability			19		38
			719		416
Long-term Liabilities					C
Lease liability			6 725		<u> </u>
			125		722
Shareholders' Equity					_
Share capital	7		52,203		52,174
Class B shares	7		2,399 4,834		2,399
Contributed surplus Warrants	7 7		4,834 3,152		4,597 3,152
Deficit	1		(42,306)		(37,474)
South			20,282		24,848
		\$	21,007	\$	25,270
		<u>,</u>	,		, -

Approved on behalf of the Board:

/s/ "Dennis Hancock"

/s/ "Kevin Puloski"

Interim Condensed Consolidated Statements of Loss and Comprehensive Loss (Unaudited, in thousands of Canadian Dollars, except for per share amounts)

		For the three month period ended,		For the six month period ended,	
		September 30,	September 30,	September 30,	September 30,
	Note	2022	2021	2022	2021
Expenses					
General and administrative	8	1,163	1,045	1,768	2,030
Research and development		453	197	698	1,100
Stock based compensation	8	63	1,169	237	1,233
Amortization of intangible assets	5	87	87	174	173
Depreciation of capital assets and right-of use					
assets		24	25	48	51
Net loss before other items		1,790	2,523	2,925	4.587
		1,790	2,525	2,925	4,007
Other items					
Loss from equity accounted associates		-	20	-	42
Fair value loss on equity investments	6	1,249	410	1,990	453
Investment income and other		(57)	(25)	(80)	(25)
Interest earned on note receivable		(2)	(2)	(3)	(3)
		1,190	403	1,907	467
		1,190	403	1,907	407
Net loss and comprehensive loss for the					
period		2,980	2,926	4,832	5,054
Basic and diluted loss per share		\$ (0.01)	\$ (0.01)	\$ (0.01) \$	6 (0.02)
					· · ·
Weighted average number of shares outstanding		200 652 404	329,285,924	200 650 675	328,979,094
ouisianung		329,653,424	329,203,924	329,650,675	320,979,094

Interim Condensed Consolidated Statements of Changes in Equity (Unaudited, in thousands of Canadian Dollars, except for per share amounts)

	Class B	Class B						
	Non-voting	Non-voting	Common Shares	Common Shares	Contributed		Т	otal Shareholders'
	Number of Shares	Share Capital	Number of shares	Share capital	surplus	Warrants	Deficit	Equity
		\$		\$	\$	\$	\$	\$
Balance at March 31, 2021	50,056,229	2,399	327,837,591	51,706	1,006	3,152	(27,765)	30,498
Exercise of stock options	-	-	600,000	68	(23)	-	-	45
Issuance of stock options	-	-	-	-	1,233	-	-	1,233
Shares for services	-	-	89,458	34	-	-	-	34
Exercise of warrants	-	-	885,000	350	-	-	-	350
Net loss for the period	-	-	-	-	-	-	(5,054)	(5,054)
Balance at September 30, 2021	50,056,229	2,399	329,412,049	52,158	2,216	3,152	(32,819)	27,106
Balance at March 31, 2022	50,056,229	2,399	329,581,549	52,174	4,597	3,152	(37,474)	24,848
Issuance of stock options	-	-	-	-	237	-	-	237
Shares issued for services	-	-	71,875	29	-	-	-	29
Net loss for the period	-	-	-	-	-	-	(4,832)	(4,832)
Balance at September 30, 2022	50,056,229	2,399	329,653,424	52,203	4,834	3,152	(42,306)	20,282

MOUNTAIN VALLEY MD HOLDINGS INC. Interim Condensed Consolidated Statements of Cash flows (Unaudited, in thousands of Canadian Dollars)

			th period ended, nber 30,
	Note	2022	2021
OPERATING ACTIVITIES			
Net loss for the period	\$	(4,832)	\$ (5,054)
Adjustments for:			
Common shares issued for consulting services		29	34
Fair value loss on equity investments	6	1,990	453
Loss from equity accounted associates	-	-	42
Stock based compensation	8	237	1,233
Amortization of intangible assets	5	174	173
Depreciation of capital assets and right-of use assets	Ũ	48	51
Interest earned on convertible note		(3)	(3)
		(0.257)	(2.071)
Changes in non-cash operating working capital		(2,357)	(3,071)
HST receivable		(6)	(72)
Prepaid expenses and deposits		125	358
Accounts payable		301	(430)
		501	(+50)
Net cash used in operating activities:		(1,937)	(3,215)
INVESTING ACTIVITIES			
Cash received from sale of investment in associate		352	_
Cash paid to acquire intellectual property	5	(13)	(44)
	5	(10)	()
Net cash used in investing activities:		339	(44)
FINANCING ACTIVITIES			
Exercise of stock options		_	45
Exercise of warrants		-	350
Net cash received from financing activities:			005
אפו כמאו ופנפועפט ווטווו ווומווטווט מנוועונופא.		-	395
Net change in cash		(1,598)	(2,864)
Cash and cash equivalents - Beginning of period		14,221	19,510
Cash and cash equivalents - End of period	\$	12,623	\$ 16,646

Notes to the Interim Condensed Consolidated Financial Statements Six months ended September 30, 2022 and September 30, 2021 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

1. NATURE OF OPERATIONS

Mountain Valley MD Holdings Inc. ("MVMDH" or the "Company"), was incorporated under the provisions of the British Columbia Business Corporations Act on March 8, 2005. The Company is building a world-class health and wellness organization centred around the implementation of its patented Quicksome[™] oral drug formulation and delivery technologies to innovate industry leading products that are sought out globally.

The Company's common shares trade on the Canadian Securities Exchange under the new ticker symbol "MVMD."

The address of the Company's registered and records office is 610 - 475 West Georgia Street, Vancouver, BC V6B 4M9 and the principal place of business is 260 Edgeley Boulevard, Unit 4, Vaughan, Ontario, Canada, L4K 3Y4.

2. BASIS OF PRESENTATION

a) Statement of compliance

These interim condensed consolidated financial statements have been prepared in accordance with International Accounting Standard 34, Interim Financial Reporting using accounting policies consistent with International Financial Reporting Standards as issued by the International Accounting Standards Board ("IFRS").

The Company's board of directors approved the release of these interim condensed consolidated financial statements on November 28, 2022.

b) Basis of measurement

In preparing its interim condensed consolidated financial statements, the Company makes judgments in applying its accounting policies. The judgments that have the most significant effect on the amounts recognized in the consolidated financial statements are outlined below in section c). In addition, the preparation of consolidated financial statements in conformity with IFRS requires the use of estimates that affect the amounts reported and disclosed in the consolidated financial statements and related notes. These estimates are based on management's best knowledge of the relevant facts and circumstances, having regard to previous experience, but actual results may differ materially from the amounts included in the interim condensed consolidated financial statements. Information about assumptions and other sources of estimation uncertainty as at September 30, 2022 that have a significant risk of resulting in a material adjustment to the carrying amounts of assets and liabilities within the next year are outlined below in section c).

c) Areas of judgment and estimation uncertainty

The preparation of the consolidated financial statements in conformity with IFRS requires the use of judgments and/or estimates that affect the amounts reported and disclosed in the consolidated financial statements and related notes. These judgments and estimates are based on management's best knowledge of the relevant facts and circumstances, having regard to previous experience, but actual results may differ materially from the amounts included in the consolidated financial statements.

In preparation of the interim condensed consolidated financial statements, the significant estimates and judgments made by management in applying the Company's accounting policies and the key sources of estimation uncertainty were the same as those applied to the consolidated financial statements for the year ended March 31, 2022.

Notes to the Interim Condensed Consolidated Financial Statements Six months ended September 30, 2022 and September 30, 2021 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

3. PURCHASE CONSIDERATION RECEIVABLE

On May 31, 2022, the Company signed a share purchase agreement to dispose of its shareholdings in its investment in associate, Sativa Nativa SAS for \$426. The Company received \$352 and the final payment of \$74 remains outstanding.

4. PREPAID EXPENSES AND DEPOSITS

	September 30, 2022	March 31, 2022
	\$	\$
Prepaid	462	587
Lease deposits	18	18
	480	605

5. INTANGIBLE ASSETS

On December 20, 2019, Mountain Valley MD Inc. entered into an intellectual property asset purchase agreement with a private Delaware corporation in the business of developing, manufacturing and licensing desiccated liposomes. The Company acquired a portfolio of patents, and trademarks. Management determined all the value is attributable to the patents.

The Company's intellectual property consists of the following:

\$
5,257
13
5,270
739
174
913
4,357
4,518
-

a) The Company recorded additions of \$13 during the six-month period ended September 30, 2022 related to direct costs to acquire new patents.

b) The Company recorded \$174 of depreciation expense during the six-month period ended September 30, 2022 based on the estimated useful life of the portfolio of patents.

Notes to the Interim Condensed Consolidated Financial Statements Six months ended September 30, 2022 and September 30, 2021 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

6. EQUITY INVESTMENTS

The following summarizes the Company's investments at September 30, 2022:

			Unrealized	
	March 31,		Gains /	September
	2022	Additions	(Losses)	30, 2022
	\$	\$	\$	\$
Sixth Wave Innovations Inc. (a)	55	-	(41)	14
Palisades Goldcorp Ltd. (b)	1,806	-	(1,007)	799
Nevada King Gold Corp. (b)	1,841	-	(900)	941
Mexican Gold Mining Corp. (b)	18	-	(10)	8
Radio Fuels Energy Corp. (b)	86	-	(47)	39
Goldspot Discoveries Corp. (b)	-	36	(21)	15
Circadian Wellness Corp. (c)	1,222	-	-	1,222
	5,028	36	(2,026)	3,038

a) Sixth Wave Innovations Inc.

As at September 30, 2022, management re-valued the investment to \$14 (September 30, 2022: \$97) based on Level 1 input under the IFRS 13 fair value hierarchy using the trading price of Sixth Wave Innovations Inc. as at September 30, 2022.

b) Class B investments (Note 12 – Subsequent Event)

On November 18, 2019, the Company disposed of its shares of Desert Hawk Resources Inc. to Casino Gold Corp. Casino Gold Corp. issued 10,000,000 shares to the Company which represented approximately 5.8% of Casino Gold's issued and outstanding shares.

In January 2020, Casino Gold Corp completed a plan of arrangement in which Casino Gold Corp. was split into two private companies. On October 14, 2021, Palisades Goldcorp Ltd. completed a plan of arrangement to distribute equity shares to shareholders of Palisades Goldcorp Ltd. The Company now owns the following equity investments now referred to as (the "Class B investments"):

- 4,091,325 common shares of Nevada King Gold Corp. (formerly Nevada King Mining Ltd, and formerly 1234721 B.C. Ltd.)
- 799,000 common shares of Palisade Goldcorp Ltd.
- 443,147 common shares of Mexican Gold Mining Corp.
- 326,339 common shares of Radio Fuels Energy Corp.
- 56,735 common shares of Goldspot Discoveries Corp.

As at September 30, 2022, management fair valued Palisade Goldcorp Ltd. and Nevada King Gold Corp. using Level 3 inputs under the IFRS 13 fair value hierarchy. The fair value was based on the most recent private sale subsequent to period end (Note 12). The fair value of the investment in Palisade Goldcorp Ltd. and Nevada King Gold Corp. has been reduced by the fair value of the distributed equity shares noted in the above paragraph.

As at September 30, 2022, management fair valued, Mexican Gold Mining Corp., Goldspot Discoveries Corp, and Radio Fuels Energy Corp., based on Level 1 inputs under the IFRS 13 fair value hierarchy. The fair value was determined using the market trading price as at September 30, 2022.

Prior to the amalgamation, shareholders of the Company (formerly, Meadow Bay Gold Corporation) received one additional Class B share of the Company for each common share held.

Notes to the Interim Condensed Consolidated Financial Statements Six months ended September 30, 2022 and September 30, 2021 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

.... Note 6. EQUITY INVESTMENTS (Continued)

The special rights and restrictions of the Class B shares provide that if the following occurs, the Company will redeem all of the outstanding Class B shares for an amount equal to the redemption price:

- the Company decides, by way of a director's resolution to distribute the Class B Investments (now Palisade Goldcorp Ltd., Nevada King Gold Corp., Mexican Gold Mining Corp., and Radio Fuels Energy Corp.); or
- the Company completes the sale of all or any portion of the Class B Investments,

Since the Company has discretion over any distribution or disposal that would require a redemption of the Class B shares, the above special rights and restrictions do not result in a liability classification. The Class B shares have therefore been presented as equity

c) Circadian Wellness Corp.

The Company owns 1,222,222 shares (post 3:1 share split on May 27, 2021) of Circadian Wellness Corp. a private Ontario corporation focusing on mushroom farming, extraction, clinical research and development, and end-user consumer health and wellness products and retreats.

As at September 30, 2022, management fair valued Circadian Wellness Corp. using Level 3 inputs under the IFRS 13 fair value hierarchy. The fair value was based on the most recent private financing done by Circadian Wellness Corp.

7. SHARE CAPITAL

a) Share Capital

Authorized

The Company has authorized share capital of:

- Unlimited Common Shares without par value.
- 50,056,229 Class B Non-Voting shares (Note 6(b))

Issued and outstanding

The Company has issued share capital of 329,653,424 Common Shares and 50,065,229 Non-Voting Class B shares.

Share issuances during the six months ended September 30, 2022

The Company issued 71,875 shares for consulting services at a deemed price of \$0.40 for a value of \$29.

Notes to the Interim Condensed Consolidated Financial Statements Six months ended September 30, 2022 and September 30, 2021 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

.... Note 7. SHARE CAPITAL (Continued)

b) Stock Options

The continuity of the Company's stock options is as follows:

	Outstanding Options	Weighted Average Exercise Price
		\$
Balance at March 31, 2021	12,798,500	0.49
lssued	7,295,000	0.29
Forfeited	(200,000)) 1.45
Cancelled	(2,590,000)) 2.04
Excercised	(600,000)) 0.07
Balance at March 31, 2022	16,703,500	0.16
Issued	50,000	0.05
Balance at September 30, 2022	16,753,500	0.16

The following table summarizes the stock options outstanding at September 30, 2022:

Evoir / Date	Number	Weighted Average Exercise Price	Options exercisable
Expiry Date	Number	THEE	exercisable
March 13, 2025 May 1, 2025 May 3, 2025 December 1, 2025 December 14, 2025 July 14, 2026	3,785,000 250,000 4,288,500 135,000 1,000,000 3,640,000	0.07 0.075 0.05 0.095 0.29 0.27	3,785,000 250,000 4,288,500 135,000 1,000,000 3,640,000
August 1, 2026	1,000,000	0.365	1,000,000
December 13, 2026	80,000	0.135	40,000
January 25, 2027	2,525,000	0.22	1,262,500
April 7, 2022	50,000	0.13	10,000
	16,753,500	0.16	15,411,000

c) Warrants

The continuity of the Company's share purchase warrants is as follows:

	Outstanding	Weighted Average Remaining	Weighted Average Exercise
	Warrants	Life (Years)	Price
			\$
March 31, 2022	16,510,878		0.44
Exercised	(885,000)		0.35
Expired	(1,498,115)		1.05
Balance at September 30, 2022 and March 31, 2022	14,127,763	0.26	0.38

Notes to the Interim Condensed Consolidated Financial Statements Six months ended September 30, 2022 and September 30, 2021 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

.... Note 7. SHARE CAPITAL (Continued)

The following table summarizes the share purchase warrants outstanding at September 30, 2022:

Expiry Date	Number	Weighted Average Exercise Price
July 11, 2023	875,000	0.48
December 18, 2022	3,273,593	0.13
December 21, 2022	9,979,170	0.45
	14,127,763	0.38

d) Restricted Share Units

Pursuant to the Company's Restricted Share Unit ("RSU") Incentive Plan approved by the board of directors of the Company on January 20, 2022, restricted stock units to acquire common shares of the Company may be granted to specified service providers of the Company in accordance with the terms and conditions of the plan. Upon vesting, each RSU entitles the participant to receive one common share, provided that the participant is continuously employed with or providing services to the Company. RSUs track the value of the underlying common shares, but do not entitle the recipient to the underlying common shares until such RSUs vest, nor do they entitle a holder to exercise voting rights or any other rights attached to ownership or control of the common shares, until the RSU vests and the RSU participant receives common shares.

On January 25, 2022, the Company issued 875,000 RSU's to directors, officers, and consultants of the Company that vest over 1 year. At September 30, 2022, there were 875,000 RSUs outstanding (September 30, 2021 – nil). During the period ended September 30, 2022, the Company recorded \$Nil (September 30, 2021 - \$Nil) as stock-based compensation for the fair value of the RSUs issued.

8. RELATED PARTY TRANSACTIONS

Key Management includes personnel having the authority and responsibility for planning, directing and controlling the Company and includes the directors and executive officers.

	Six months ended September 30, 2022	Six months ended September 30, 2021
	September 30, 2022	\$
Short-term benefits	332	245
Stock based compensation	143	844
	475	1,089

There are \$Nil amounts included in accounts payable and accrued liabilities as at September 30, 2022 and March 31, 2022 owing to Key Management.

Notes to the Interim Condensed Consolidated Financial Statements Six months ended September 30, 2022 and September 30, 2021 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

9. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT

The Company's financial instruments include cash and cash equivalents, note receivable, equity investments, accounts payable and accrued liabilities, and lease liability. The carrying amounts of these financial instruments are a reasonable estimate of their fair values based on their current nature and current market rates for similar financial instruments.

Financial instruments measured at fair value are classified into one of three levels in the fair value hierarchy according to the relative reliability of inputs used to estimate the fair values. The three levels of the fair value hierarchy are:

Level 1 – Unadjusted quoted prices in active markets for identical assets and liabilities; Level 2 – Inputs other than quoted prices that are observable for the asset or liability either directly or indirectly; and Level 3 – Inputs that are not based on observable market data.

As at September 30, 2022, the Company did not have any financial assets and liabilities which are measured at fair value, other than accounts receivable and equity investments. There were no transfers between Level 1, 2 or 3 during the six-month period ended September 30, 2022.

a) Credit risk

Credit risk is the risk that the financial benefits of contracts with a specific counterparty will be lost if a counterparty defaults on its obligations under the contract. Credit risk arises from cash, purchase consideration receivable, and note receivable. The amount of credit risk related to cash and cash equivalents is considered insignificant as the Company's funds are held with a large Canadian bank. The Company obtains financial information from the creditor to determine the carrying amounts of the accounts receivable and note receivable.

The credit risk for both the cash and cash equivalent, purchase consideration receivable and note receivable is monitored quarterly, and any change is reflected as an adjustment through expected credit loss.

b) Liquidity risk

Liquidity risk is the risk that the Company will not be able to meet its financial obligations as they fall due. The Company manages liquidity risk through the management of its capital structure. The Company monitors and reviews current and future cash requirements and matches the maturity profile of financial assets and liabilities.

As at September 30, 2022, the Company's financial liabilities have contractual maturities as summarized below:

	Due within		
	0-12 months \$	1-2 years \$	2-3 years \$
Accounts payable and accrued liabilities	560	-	-
Lease liability	19	6	-
Total	579	6	-

c) Market risk

Market risk is the risk that the fair value of future cash flows of a financial instrument will fluctuate because of changes in market prices and is comprised of currency risk, interest rate risk, and other price risk.

Notes to the Interim Condensed Consolidated Financial Statements Six months ended September 30, 2022 and September 30, 2021 (Unaudited, in thousands of Canadian dollars, except for per share amounts)

.... Note 9. FINANCIAL INSTRUMENTS AND RISK MANAGEMENT (Continued)

Sensitivity analysis

The Company has completed a sensitivity analysis to estimate the impact on net comprehensive loss which a change in the equity investments would have on the Company during the six-month period ended September 30, 2022. As a result, a 10% change in the equity investments will translate to a \$181 (September 30, 2021, \$460) gain or loss from equity investments.

10. SEGMENT INFORMATION

Management has determined that the Company has one reportable operating segment, being research and development of its delivery, solubility, and adjuvant technologies. This segment accounts for all of the Company's operating expenses. Determination of the operating segment was based on the level of financial reporting to the Company's chief decision makers.

All of the Company's fixed assets are located in Canada. The Company has investments in associates (Note 4) which have been sold during the period, and licenses that are located in Colombia. The licenses have been written down to \$nil as management determined them to be impaired. The Company's revenue is derived from Canada.

11. CAPITAL MANAGEMENT

The Company manages its cash, common shares, warrants and share purchase options as capital. The Company's objectives when managing capital are to safeguard its ability to continue as a going concern and to maintain a flexible capital structure which optimizes the costs of capital at an acceptable risk.

The Company manages the capital structure and makes adjustments to it in light of changes in economic conditions and the risk characteristics of the underlying assets. To maintain or adjust the capital structure, the Company may attempt to issue new shares, acquire or dispose of assets or adjust the amount of cash held.

12. SUBSEQUENT EVENTS

On October 4, 2022, the Company made an equity investment of \$203 in Agrarius Corp, a private US corporation, and parent company of Agroresults, Inc.

On November 4, 2022, the Company converted the note receivable of \$115 into common shares of Agroresults, Inc. a private Canadian company.

On November 7, 2022, the Company sold its Class B investments (Note 6) for gross proceeds of \$1,798. The Company has initiated the process of distributing the proceeds to the holders of Class B Shares to be completed by the end of December 2022.